At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2,640 enrolled
Drug / intervention
HRV vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Assess the Efficacy, Immuno & Safety of 2 Doses of GSK HRV Vaccine at Different Virus Concentrations in Healthy Infants Aged 2 Months & Previously Uninfected With HRV, Concurrently Given With DTPw-HBV, Hib.
In Brief
A Phase 2 clinical trial evaluating HRV vaccine for Infections, Rotavirus. Completed, enrolled 2,640 participants.
Detailed Summary
The purpose of this study is to test how infants respond to different strengths of the human rotavirus vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Rotavirus
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2001
Primary CompletionApr 2003
First PostedOct 2006
TodayJul 2026
First PostedOct 9, 2006
Enrollment StartMay 31, 2001
Primary CompletionApr 30, 2003
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.7 years ago
Interventions
HRV vaccinebiological